STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.